Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

20250 citationsJournal Articlegold Open Access

Authors

Elizabeth J. Kelly · University of Oxford

Melanie Greenland · University of Oxford

Philip de Whalley · University of Oxford

Grace C. Macaulay · University of Oxford

Parvinder K. Aley · University of Oxford

Emma Plested · University of Oxford

S Koleva ·

Abstract

All booster regimens evaluated elicited a robust immune response. 10 μg fractional adult BNT162b2 vaccine demonstrated similar immunogenicity compared with 30 μg BNT162b2 and superior immunogenicity compared with 10 μg paediatric BNT162b2 vaccine. Fractional doses of the adult BNT162b2 vaccine are an alternative to the paediatric formulation for booster campaigns in adolescents.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Vaccine Coverage and Hesitancy Immune responses and vaccinations

Publication Details

Published in: Journal of Infection

Volume 92, Issue 1, pp. 106663-106663

DOI: 10.1016/j.jinf.2025.106663

Field-Weighted Citation Impact: 0.00

Command Palette

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Authors

Abstract

Topics & Keywords

Publication Details